We previously highlighted the importance of TNF-α in the systemic involvement of psoriasis at every level: therefore, it is not surprising that its inhibitors are indicated, in cases of patients with other inflammatory “comorbidities” (i.e., IBD, PsA, uveitis) Moreover, TNF-α inhibitors entered the market before others, and therefore the amount of data supporting their efficacy and safety profile is wider. The gene discussed is TNF; the disease is inflammatory bowel disease.